Indivior UK Limited

Tolmar Therapeutics, Inc.

Atrix Laboratories, Inc.

Rb Pharmaceuticals Limited

Medlogic Global Corporation

Tolmar, Inc.

Artix Laboratories, Inc.

Tolmar International Limited

Richard L Norton

Mingxing Zhou

Andrew Watkins

Eric Dadey

John Middleton

Richard L Dunn

Deryl D Swanbom

Kenneth S Peterson

Alan M Polson

Bryan K Lowe

Charles P Cox

Qi Li

Lester Moore

Daniel Barnhill

Trant Holt

Arthur J Tipton

Ian N Askill

Cody L Yarborough

Dominic G Madril

Rajan Bawa

Christopher J Barrett

Michael R Duncan

Shane C Karnik

Stephen Michael Knight

A medication component mixing system is formed of a first syringe, such as a female syringe, and a second syringe such as a male syringe, wherein the system is configured to mix a female portion and a male portion of the medication. The female syringe and the male syringe mechanically couple to one another in an end-to-end fashion for mixing of the contents of the female and male portions.

Syringe system

A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced 'initial burst' effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use.

Low-burst polymers and methods to produce polymer

The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.

Injectable flowable composition comprising buprenorphine

The disclosure provides extended release pharmaceutical formulations comprising an opioid, particularly buprenorphine, a biocompatible organic solvent, and, optionally, a glycol, for use in the treatment of pain or opioid dependence. The pharmaceutical formulations are in the form of a pharmaceutical solution.

Sustained-release buprenorphine solutions

This disclosure relates to a buprenorphine sustained release delivery system for treatment of conditions ameliorated by buprenorphine compounds. The sustained release delivery system includes a flowable composition containing a suspension of buprenorphine, a metabolite, or a prodrug thereof.

Compositions comprising buprenorphine

Injectable composition comprising buprenorphine

Low-burst polymers and methods to produce polymers

Growing community of inventors

Fort Collins, CO, United States of America

Richard L Norton